Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden
Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden
BACKGROUND: The prevalence of multimorbidity (the presence of two or more long-term conditions) is rising internationally. Multimorbidity affects patients by increasing their burden of symptoms, but is also likely to increase the self-care demands, or treatment burden, that they experience. Treatment burden refers to the effort expended in operationalising treatments, navigating healthcare systems and managing relations with healthcare providers. This is an important problem for people with chronic illness such as stroke. Polypharmacy is an important marker of both multimorbidity and burden of treatment. In this study, we examined the prevalence of multimorbidity and polypharmacy in a large, nationally representative population of primary care patients with and without stroke, adjusting for age, sex and deprivation.
METHODS:
A cross-sectional study of 1,424,378 participants aged 18 years and over, from 314 primary care practices in Scotland that were known to be demographically representative of the Scottish adult population. Data included information on the presence of stroke and another 39 long-term conditions, plus prescriptions for regular medications.
RESULTS:
In total, 35,690 people (2.5%) had a diagnosis of stroke. Of the 39 comorbidities examined, 35 were significantly more common in people with stroke. Of the people with a stroke, the proportion that had one or more additional morbidities present (94.2%) was almost twice that in the control group (48%) (odds ratio (OR) adjusted for age, sex and socioeconomic deprivation 5.18; 95% confidence interval (CI) 4.95 to 5.43). In the stroke group, 12.6% had a record of 11 or more repeat prescriptions compared with only 1.5% of the control group (OR adjusted for age, sex, deprivation and morbidity count 15.84; 95% CI 14.86 to 16.88). Limitations include the use of data collected for clinical rather than research purposes, a lack of consensus in the literature on the definition of certain long-term conditions, and the absence of statistical weighting in the measurement of multimorbidity, although the latter was deemed suitable for descriptive analyses.
CONCLUSIONS:
Multimorbidity and polypharmacy were strikingly more common in those with a diagnosis of stroke compared with those without. This has important implications for clinical guidelines and the design of health services.
151-[9pp]
Gallacher, Katie I.
60585855-f553-4f94-a37c-05a9cb8f83e6
Batty, G.
d26f9a85-317e-470b-aeeb-1713061f10d5
McLean, Gary
f3855be3-7b25-4ea4-a2e9-5d9148808332
Mercer, Stewart W.
66234c9c-400d-4e2d-bf01-151d1a33b762
Guthrie, Bruce
806b16e2-098c-4fa9-94db-f6f022bd1173
May, Carl R.
17697f8d-98f6-40d3-9cc0-022f04009ae4
Langhorne, Peter
ab0e4d6a-3d2e-4b1b-85c0-994b5b93cf63
Mair, Frances S.
303709c7-028a-44b9-b6da-e14f2d834f2b
3 October 2014
Gallacher, Katie I.
60585855-f553-4f94-a37c-05a9cb8f83e6
Batty, G.
d26f9a85-317e-470b-aeeb-1713061f10d5
McLean, Gary
f3855be3-7b25-4ea4-a2e9-5d9148808332
Mercer, Stewart W.
66234c9c-400d-4e2d-bf01-151d1a33b762
Guthrie, Bruce
806b16e2-098c-4fa9-94db-f6f022bd1173
May, Carl R.
17697f8d-98f6-40d3-9cc0-022f04009ae4
Langhorne, Peter
ab0e4d6a-3d2e-4b1b-85c0-994b5b93cf63
Mair, Frances S.
303709c7-028a-44b9-b6da-e14f2d834f2b
Gallacher, Katie I., Batty, G., McLean, Gary, Mercer, Stewart W., Guthrie, Bruce, May, Carl R., Langhorne, Peter and Mair, Frances S.
(2014)
Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden.
BMC Medicine, 12 (1), .
(doi:10.1186/s12916-014-0151-0).
(PMID:25280748)
Abstract
BACKGROUND: The prevalence of multimorbidity (the presence of two or more long-term conditions) is rising internationally. Multimorbidity affects patients by increasing their burden of symptoms, but is also likely to increase the self-care demands, or treatment burden, that they experience. Treatment burden refers to the effort expended in operationalising treatments, navigating healthcare systems and managing relations with healthcare providers. This is an important problem for people with chronic illness such as stroke. Polypharmacy is an important marker of both multimorbidity and burden of treatment. In this study, we examined the prevalence of multimorbidity and polypharmacy in a large, nationally representative population of primary care patients with and without stroke, adjusting for age, sex and deprivation.
METHODS:
A cross-sectional study of 1,424,378 participants aged 18 years and over, from 314 primary care practices in Scotland that were known to be demographically representative of the Scottish adult population. Data included information on the presence of stroke and another 39 long-term conditions, plus prescriptions for regular medications.
RESULTS:
In total, 35,690 people (2.5%) had a diagnosis of stroke. Of the 39 comorbidities examined, 35 were significantly more common in people with stroke. Of the people with a stroke, the proportion that had one or more additional morbidities present (94.2%) was almost twice that in the control group (48%) (odds ratio (OR) adjusted for age, sex and socioeconomic deprivation 5.18; 95% confidence interval (CI) 4.95 to 5.43). In the stroke group, 12.6% had a record of 11 or more repeat prescriptions compared with only 1.5% of the control group (OR adjusted for age, sex, deprivation and morbidity count 15.84; 95% CI 14.86 to 16.88). Limitations include the use of data collected for clinical rather than research purposes, a lack of consensus in the literature on the definition of certain long-term conditions, and the absence of statistical weighting in the measurement of multimorbidity, although the latter was deemed suitable for descriptive analyses.
CONCLUSIONS:
Multimorbidity and polypharmacy were strikingly more common in those with a diagnosis of stroke compared with those without. This has important implications for clinical guidelines and the design of health services.
Text
Stroke multimorbidity and polypharmacy.pdf
- Version of Record
More information
Accepted/In Press date: 12 August 2014
e-pub ahead of print date: 3 October 2014
Published date: 3 October 2014
Organisations:
Faculty of Health Sciences
Identifiers
Local EPrints ID: 383935
URI: http://eprints.soton.ac.uk/id/eprint/383935
PURE UUID: 26e79859-0173-48c3-85ae-823db01a7524
Catalogue record
Date deposited: 30 Nov 2015 14:24
Last modified: 14 Mar 2024 21:50
Export record
Altmetrics
Contributors
Author:
Katie I. Gallacher
Author:
G. Batty
Author:
Gary McLean
Author:
Stewart W. Mercer
Author:
Bruce Guthrie
Author:
Carl R. May
Author:
Peter Langhorne
Author:
Frances S. Mair
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics